Cypros Pharmaceutical Appoints Vice President of Sales and Marketing.

CARLSBAD, Calif.--(BUSINESS WIRE)--March 23, 1999--Cypros Pharmaceutical Corp. (AMEX:CYP) announced today the hiring of John Lee to the newly-created post of vice president of sales and marketing.

Lee has more than 20 years of highly successful sales and marketing experience at both large (G. D. Searle) and emerging pharmaceutical firms (Unimed). He has directed two major highly successful product launches and achieved continued and impressive sales growth throughout his career. Lee will be directing the launch of the company's new Dermaflo(TM) product line, as well as increasing the size of the company's sales and marketing department.

"This is an exciting time for our company as we prepare to launch a range of new products, build our sales organization and expand markets for our existing products," commented Paul J. Marangos, chief executive officer of Cypros. "John brings a unique combination of energy, experience and intelligence to this task."

Cypros Pharmaceutical is engaged in the development and marketing of drug products for the hospital market. The company currently has three products on the market, Glofil, Inulin and Ethamolin(R), is preparing to launch two proprietary, extended-release wound-care products using the Dermaflo(TM) technology; and, is developing its two lead drugs, Cordox(TM) and Ceresine(TM), for a variety of ischemic disorders.

This news release contains forward looking statements, which involve risks and uncertainties. Such statements are subject to certain factors, which may cause the company's plans to differ. Factors that may cause such differences include, but are not limited to, the risks discussed in the company's Form 10-K for the fiscal year ended July 31, 1998 and the Risk Factors section of the company's Registration Statement No. 333-25661.